How Emrelis Is Expanding Treatment Options for Solid Tumors With C-MET Overexpression
July 23rd 2025Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact by expanding into other solid tumors with high c-MET overexpression, beyond its current focus on non-small cell lung cancer.
Emrelis Approval Highlights FDA Confidence in ADC Oncology Treatments
July 22nd 2025Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis marks a pivotal moment for ADC therapies in oncology, reflecting the FDA’s growing confidence in their safety and efficacy and accelerating the shift toward precision medicine in cancer treatment.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
July 18th 2025Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Study: TV Ads Nearly Match Doctors in Driving Awareness of New Medications Among US Consumers
July 17th 2025Research from a recent Cadent study reveals the growing impact of TV and connected TV advertising in raising medication awareness across diverse demographic groups, highlighting shifting dynamics in how patients discover treatment options.
Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma
July 17th 2025Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to target advanced endometrial carcinoma through dual mechanisms of action and WNT pathway modulation.
Eisai Highlights Long-Term Efficacy of Lenvima in Advanced HCC Treatment
July 16th 2025Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating unresectable hepatocellular carcinoma.